GCG and obesity due to melanocortin 4 receptor deficiency: Administration of OXM to rodents and humans reduces food intake and increases energy expenditure, generating significant weight loss and highlighting OXM as a potential pharmacologic treatment for obesity.3, 4 Due to the short in vivo half-life of native OXM,5 it is necessary to produce long-lasting analogues for clinical use.